FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2745135075> ?p ?o ?g. }

• W2745135075 endingPage "625" @default.
• W2745135075 startingPage "625" @default.
• W2745135075 abstract "625 Background: Trastuzumab was approved in the United States (US) in September 1998 for the treatment of HER2+ metastatic breast cancer (MBC). This model estimates the total number of life years saved (LYS) in US women treated with trastuzumab over a 15-year period (1999-2013). Methods: Using US population estimates and cancer registry-based incidence data, we estimated the number of women with recurrent stage I-III or de novo stage IV HER2+ MBC by year, age, hormone receptor, and nodal status. Trastuzumab utilization was based on published studies of HER2 testing rates, true positive rates in the community, and treatment initiation rates. Survival was estimated by extrapolating survival data pooled across 5 trials and 2 observational studies separately for women treated with trastuzumab and with chemotherapy alone. Few studies reported survival in women with HER2+ MBC without trastuzumab (N=3). Sensitivity analyses were conducted by estimating overall survival from the initial phase 3 trial (67% of placebo patients crossed over to trastuzumab after progression; HR=0.80), and assuming a higher risk reduction to account for crossover effects in clinical trials (HR=0.60). Results: In the base case, approximately 83,462 women with HER2+ MBC were estimated to receive 1 st line trastuzumab over a 15-year period. The pooled median overall survival across studies without and with trastuzumab was 21.2 and 35.5 months, respectively. Patients were projected to live a total of 216,290 life years if trastuzumab had not been available and if they received chemotherapy only. These same patients were estimated to live a total of 294,877 life years with first-line trastuzumab, for an incremental benefit of 78,587 LYS. In sensitivity analysis, total LYS ranged from 48,334-96,360. Conclusions: Real-world evidence supports a median overall survival of approximately 36 months in women with HER2+ MBC receiving 1 st line trastuzumab. Using a population-based, conservative model, we found that trastuzumab use has resulted in > 75,000 life years over 15 years in women with HER2+ MBC. Future research is warranted to examine the characteristics, experiences, and outcomes among women living longer with HER2+ MBC." @default.
• W2745135075 created "2017-08-17" @default.
• W2745135075 creator A5006260782 @default.
• W2745135075 creator A5018773741 @default.
• W2745135075 creator A5032187510 @default.
• W2745135075 creator A5047960113 @default.
• W2745135075 creator A5057089566 @default.
• W2745135075 creator A5072015843 @default.
• W2745135075 date "2013-05-20" @default.
• W2745135075 modified "2023-09-25" @default.
• W2745135075 title "Estimated life years saved with trastuzumab in first-line HER2+ metastatic breast cancer from 1999 to 2013." @default.
• W2745135075 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.625" @default.
• W2745135075 hasPublicationYear "2013" @default.
• W2745135075 type Work @default.
• W2745135075 sameAs 2745135075 @default.
• W2745135075 citedByCount "0" @default.
• W2745135075 crossrefType "journal-article" @default.
• W2745135075 hasAuthorship W2745135075A5006260782 @default.
• W2745135075 hasAuthorship W2745135075A5018773741 @default.
• W2745135075 hasAuthorship W2745135075A5032187510 @default.
• W2745135075 hasAuthorship W2745135075A5047960113 @default.
• W2745135075 hasAuthorship W2745135075A5057089566 @default.
• W2745135075 hasAuthorship W2745135075A5072015843 @default.
• W2745135075 hasConcept C121608353 @default.
• W2745135075 hasConcept C126322002 @default.
• W2745135075 hasConcept C143998085 @default.
• W2745135075 hasConcept C2775930923 @default.
• W2745135075 hasConcept C2779786085 @default.
• W2745135075 hasConcept C2908647359 @default.
• W2745135075 hasConcept C29456083 @default.
• W2745135075 hasConcept C530470458 @default.
• W2745135075 hasConcept C71924100 @default.
• W2745135075 hasConcept C99454951 @default.
• W2745135075 hasConceptScore W2745135075C121608353 @default.
• W2745135075 hasConceptScore W2745135075C126322002 @default.
• W2745135075 hasConceptScore W2745135075C143998085 @default.
• W2745135075 hasConceptScore W2745135075C2775930923 @default.
• W2745135075 hasConceptScore W2745135075C2779786085 @default.
• W2745135075 hasConceptScore W2745135075C2908647359 @default.
• W2745135075 hasConceptScore W2745135075C29456083 @default.
• W2745135075 hasConceptScore W2745135075C530470458 @default.
• W2745135075 hasConceptScore W2745135075C71924100 @default.
• W2745135075 hasConceptScore W2745135075C99454951 @default.
• W2745135075 hasIssue "15_suppl" @default.
• W2745135075 hasLocation W27451350751 @default.
• W2745135075 hasOpenAccess W2745135075 @default.
• W2745135075 hasPrimaryLocation W27451350751 @default.
• W2745135075 hasRelatedWork W188069312 @default.
• W2745135075 hasRelatedWork W2001196910 @default.
• W2745135075 hasRelatedWork W2092771806 @default.
• W2745135075 hasRelatedWork W2130521606 @default.
• W2745135075 hasRelatedWork W2158916914 @default.
• W2745135075 hasRelatedWork W2401868633 @default.
• W2745135075 hasRelatedWork W2896532861 @default.
• W2745135075 hasRelatedWork W2931400096 @default.
• W2745135075 hasRelatedWork W2934076975 @default.
• W2745135075 hasRelatedWork W2342209702 @default.
• W2745135075 hasVolume "31" @default.
• W2745135075 isParatext "false" @default.
• W2745135075 isRetracted "false" @default.
• W2745135075 magId "2745135075" @default.
• W2745135075 workType "article" @default.